Alpine Immune Sciences Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Alpine Immune Sciences stock.
View analyst ratings for Alpine Immune Sciences or view top-rated stocks.

Wall Street analysts have given Alpine Immune Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alpine Immune Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Alpine Immune Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 548,000 shares, an increase of 42.2% from the February 28th total of 385,500 shares. Based on an average trading volume of 141,800 shares, the short-interest ratio is currently 3.9 days. Approximately 4.3% of the shares of the company are short sold.
View Alpine Immune Sciences' Short Interest.

Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Alpine Immune Sciences.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its earnings results on Wednesday, March, 17th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.31) by $0.04. Alpine Immune Sciences had a negative net margin of 606.16% and a negative trailing twelve-month return on equity of 80.38%.
View Alpine Immune Sciences' earnings history.

Alpine Immune Sciences' stock was trading at $2.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ALPN stock has increased by 252.2% and is now trading at $10.25.
View which stocks have been most impacted by COVID-19.

6 analysts have issued 12-month price targets for Alpine Immune Sciences' stock. Their forecasts range from $17.00 to $22.00. On average, they anticipate Alpine Immune Sciences' share price to reach $19.40 in the next twelve months. This suggests a possible upside of 89.3% from the stock's current price.
View analysts' price targets for Alpine Immune Sciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Alpine Immune Sciences include Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Arcturus Therapeutics (ARCT), Akero Therapeutics (AKRO), ESSA Pharma (EPIX), Annexon (ANNX), Radius Health (RDUS), Prothena (PRTA), Vanda Pharmaceuticals (VNDA), Merus (MRUS), Vectura Group (VEGPF), BioXcel Therapeutics (BTAI), Dyne Therapeutics (DYN), Affimed (AFMD) and Humanigen (HGEN).
View all of ALPN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN).

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPN stock can currently be purchased for approximately $10.25.

Alpine Immune Sciences has a market capitalization of $244.79 million and generates $1.74 million in revenue each year. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

Alpine Immune Sciences employs 57 workers across the globe.

The official website for Alpine Immune Sciences is www.alpineimmunesciences.com.

Alpine Immune Sciences is headquartered at 188 East Blaine Street Suite 200, Seattle WA, 98102.

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]